Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Main objectives:
Evaluate the effectiveness of an administration of 3,4-diaminopyridine (FIRDAPSE ®) in severe
botulinic poisoning in measuring the effect on electrophysiological and respiratory
parameters
Secondary Objective:
Study the natural history of electrophysiological and respiratory parameters during the
botulinic intoxication
Primary endpoint:
Clinical, electrophysiological and respiratory before and after administration of
3,4-diaminopyridine.
Study Design:
Pilot study, prospective, interventional.
Study population:
Case series (n = 8 patients) suffering from botulinic type A, respiratory failure, but with
no other organ failure
Experimental treatment :
3,4-diaminopyridine, FIRDAPSE ® (BioMarin) The dosage will be gradually increased according
to a predetermined scheme and will not exceed 60 mg / day and 20 mg / dose.
Statistics:
Intra-individual comparison of physiological parameters measured before and after
administration of 3,4-diaminopyridine. Electromyographic and respiratory parameters will be
measured for each patient. Then a dose of 10 mg of 3,4-diaminopyridine will be administrated.
If this dose is well tolerated and provides a relative improvement of 10% for at least one of
the parameters studied, the dose will be maintained at 10 mg for 48 hours 3 times a day then
increased to 20 mg.
The primary endpoint is the change in the amplitude of muscle response evaluated by the
subtraction of amplitude at T1.5 and T0.